EC approves new Eylea indication

The European Commission approved an MAA from Bayer AG (Xetra:BAYN) to expand the label of Eylea aflibercept to include treatment of visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO). Eylea already is approved in Europe to treat wet age-related macular degeneration (AMD). The human fusion protein that binds all forms of VEGF-A and placental growth factor (PIGF) is approved in the U.S. for wet AMD and macular edema following CRVO, and is approved for wet AMD in Japan, Australia, Switzerland and some Latin American countries. ...